Does Compounded Semaglutide Work? What the Evidence Shows
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide is not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency.
You want an honest answer before you spend money: does compounded semaglutide actually work? The short version is that semaglutide, the active ingredient, has strong clinical-trial evidence behind it, but that evidence comes from the FDA-approved brand-name product. Compounded versions are not FDA-evaluated, so you cannot assume a compounded product performs like the studied product. Here is what the evidence shows, how compounded semaglutide relates to it, and what affects whether any semaglutide works for you.
The short answer
Semaglutide has been tested for weight management in large randomized trials of the FDA-approved brand-name product, Wegovy. In those trials, participants lost a meaningful amount of weight on average. That evidence is real, and it is the reason semaglutide is talked about so much.
Here is the important distinction. The trials tested a specific, manufactured formulation. Compounded semaglutide contains semaglutide, but it is not FDA-approved, and it may differ from that formulation in purity, potency, and ingredients. The FDA has not evaluated compounded semaglutide for effectiveness, safety, or quality[1], and a PubMed search on October 16, 2026 found no published randomized controlled trials of compounded semaglutide. So the honest framing is this: the molecule has strong evidence behind it, but there is no trial evidence that any compounded product produces the same results. Results vary.
What the clinical evidence shows for semaglutide
The landmark study for semaglutide in weight management is the STEP 1 trial, published in the New England Journal of Medicine in 2021. It enrolled 1,961 adults with obesity, or with overweight plus at least one weight-related condition, who did not have diabetes. Participants were randomly assigned to once-weekly semaglutide 2.4 mg (the dose in Wegovy) or placebo, both with lifestyle intervention, for 68 weeks[2].
Participants on semaglutide had an average body weight change of -14.9% over 68 weeks, compared with -2.4% on placebo[2]. The trial also looked at how many people crossed different weight-loss thresholds, because an average alone hides how widely results are distributed.
A few things are worth keeping in mind when you read those numbers. They describe participants taking the FDA-approved brand-name product in a clinical trial, not compounded semaglutide. They are averages and proportions across a large group, not a prediction for any one person. And participants in both groups received lifestyle intervention alongside the study drug, which is part of why the plan around the medication matters.
The same trial reported side effects. Nausea and diarrhea were the most common adverse events with semaglutide, usually mild to moderate and fading with time, and 4.5% of semaglutide participants stopped treatment because of gastrointestinal events, compared with 0.8% on placebo[2].
Risks on the semaglutide label
Benefits are only half the picture. The FDA label for Wegovy describes these risks, and like the trial data, it applies to the brand-name product studied, not to compounded versions[3]:
- Boxed warning. Semaglutide caused thyroid C-cell tumors in rodents. It is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans.
- Who should not use it. People with a personal or family history of MTC, people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people with a known serious hypersensitivity to semaglutide or the product’s ingredients.
- Common side effects. The most common include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, and dizziness, among others listed on the label.
- Serious warnings. These include acute pancreatitis, acute gallbladder disease, low blood sugar when used with insulin or a sulfonylurea, acute kidney injury, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation.
For a closer look at the full distribution of results and how the data breaks down, see our deeper write-up on how much weight you can lose on semaglutide.
How compounded semaglutide relates to this evidence
This is the part that matters most for your decision, so it is worth being precise.
Compounded semaglutide is made with semaglutide as its active ingredient, which is its point of connection to the clinical evidence. But the connection is the molecule, not the product. STEP 1 and the other trials behind FDA approval tested a specific, FDA-approved formulation. They did not test compounded versions, and the FDA has not reviewed any compounded semaglutide product for effectiveness, safety, or quality[1].
A few specific gaps are worth knowing about:
No trial evidence for compounded products. A PubMed search on October 16, 2026 found no published randomized controlled trials of compounded semaglutide. The published research on compounded products is mostly observational studies, case reports, and laboratory analyses. A 2026 review of compounded semaglutide and tirzepatide products sold online found many used formulations that differ from approved products, such as added vitamins or under-the-tongue forms, and concluded that evidence for their safety and efficacy is lacking[4].
Salt forms. The FDA says some compounders may be using salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate. These are different active ingredients from the one in FDA-approved semaglutide, and the FDA says it does not have information on whether they have the same chemical and pharmacologic properties[5]. A product made with a salt form cannot be assumed to work the same way.
Formulation, purity, and potency. A compounded preparation can differ from the studied brand-name product in formulation, purity, and potency. Quality depends on the pharmacy that prepares it, which is why it helps to know which pharmacy that is and how to check its license.
For all these reasons, no one can honestly say compounded semaglutide works “the same as” or is “equivalent to” the brand-name product. What can be said is that semaglutide as a molecule has been studied carefully, that compounded semaglutide contains that molecule, and that a licensed provider can weigh the available evidence against your health history when deciding whether any semaglutide product is appropriate for you. For the safety side of compounded medications, including the FDA’s adverse event reports, see our page on compounded semaglutide safety.
What affects whether it works for you
Even setting aside the brand-versus-compounded distinction, “does it work” is never only about the medication. Semaglutide reduces appetite and slows digestion, which makes it easier to eat less, but it does not override everything else. Several factors shape how much it helps any individual.
Correct dose titration. Semaglutide is started at a low dose and increased in steps over several months, which helps with tolerability[3]. Reaching and tolerating an appropriate dose, on a schedule the prescriber sets, is one of the biggest drivers of results in the trials.
Consistent weekly use. Missing doses or stretching out the schedule can keep you at lower levels longer and blunt the effect. Steady, as-directed use matters.
Accurate dosing. Compounded semaglutide often comes in multiple-dose vials measured with a syringe, not a prefilled pen. The FDA has received reports of dosing errors with compounded semaglutide, some leading to hospitalization, including confusion between milligrams, milliliters, and “units”[5]. Make sure you know your product’s concentration and exactly how to measure your dose.
Nutrition and protein. The medication makes it easier to eat less, but food choices still count. Keeping up adequate protein and a reasonable eating pattern supports better body-composition changes. Our guide on a high-protein approach while on a GLP-1 covers this in practical detail.
Activity, especially strength work. Combining the medication with regular movement, particularly resistance training, supports more favorable changes in body composition.
Sleep and stress. Chronic poor sleep and ongoing high stress can work against weight loss. These are not character flaws, they are physiology, and they are worth raising with the provider you choose.
Individual biology. People genuinely differ in how they respond to GLP-1 medications. Some respond readily, others more modestly. This is real, it is not about effort, and it is part of why a licensed provider can help you set expectations specific to you.
What a realistic timeline looks like
Weight loss on semaglutide is rarely fast or linear, and knowing that up front helps you stick with it through the slow stretch.
In the first several weeks, while the dose is low, most people feel only a modest change in appetite and may see little movement on the scale. The early weeks are often more about tolerating the medication than about results. As the dose increases over the following weeks, many people notice reduced appetite and quieter food cravings. Weight loss generally builds gradually over months as the dose reaches the maintenance level and the supporting habits take hold.
The practical takeaway is patience. If the first month feels slow, that is consistent with how the medication is designed to be started, not a sign that it is failing. For a fuller, month-by-month picture, see how long a GLP-1 takes to work.
When it may not work as expected
Sometimes results fall short of what someone hoped for. A few common reasons, most of which are addressable:
- Under-titration. Staying at a low dose for too long is a common reason results stall. The prescriber manages the dose schedule for a reason.
- Missed or inconsistent doses. Gaps in use can keep the medication from reaching steady levels.
- Dosing mistakes. With compounded vials, measuring the wrong amount in the syringe can mean too little or too much medication[5].
- Limited lifestyle support. Without adequate protein, nutrition, movement, and sleep, the medication has less to build on.
- Expectations set too high. Trial averages are not promises. Comparing your week-four progress to someone else’s six-month results, or to a headline number, can make normal progress feel like failure.
- Individual biology. Some people simply respond more modestly, and that is not something you did wrong.
There is also the point this page keeps returning to: because compounded semaglutide is not FDA-evaluated, differences in formulation, potency, or active ingredient could affect how a given product performs. A licensed provider can review your situation, check that the dose and approach make sense, and help you decide on next steps if results are not where you expected. Results vary.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedImportant disclosures
This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Results vary. Trial results describe study participants and are not a prediction for any individual. The STEP 1 figures on this page describe participants taking semaglutide 2.4 mg, the FDA-approved brand-name product, not compounded semaglutide[2].
Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed[1]. Compounded semaglutide is not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency, so identical results cannot be assumed. A prescription is required, and a licensed provider decides whether one is appropriate.
Regulatory status is subject to change. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved; it said its 503A enforcement discretion period ended after an April 24, 2025 court decision (the original end date was April 22, 2025) and its 503B period ended May 22, 2025. That FDA page was most recently updated April 1, 2026; check it for the current statement[6]. Availability of compounded semaglutide depends on federal and state law and FDA action, and cannot be guaranteed.
Wegovy is a trademark of Novo Nordisk A/S. Transformation Health is not affiliated with or endorsed by Novo Nordisk.
Transformation Health does not accept payment from providers. How we make money.
Citations
[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved and the FDA does not verify their safety, effectiveness, or quality.)
[2] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Supports: STEP 1 design and participants; mean body weight change of -14.9% vs -2.4% with placebo at 68 weeks; 86.4%, 69.1%, and 50.5% of semaglutide participants reaching 5%, 10%, and 15% reductions; nausea and diarrhea as the most common adverse events; 4.5% vs 0.8% discontinuation for gastrointestinal events.)
[3] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information, Boxed Warning and sections 2, 4, 5, and 6. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Supports: boxed warning, contraindications, warnings and precautions, common adverse reactions, stepwise dose escalation.)
[4] Belcourt J, Sapowadia A, White CM. “Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.” Ann Pharmacother. 2026;60(9):902-906. https://pubmed.ncbi.nlm.nih.gov/41689811/ (Supports: compounded products found online used formulations that differ from approved products, including added ingredients and sublingual or orally disintegrating forms; authors cite a lack of evidence for safety and efficacy.)
[5] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: salt forms as different active ingredients with unknown properties; dosing errors with compounded semaglutide, some requiring hospitalization; unit confusion.)
[6] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: semaglutide shortage resolution date and end of enforcement discretion periods.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded semaglutide is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide is not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency. Results vary. Availability of compounded semaglutide depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Wegovy is a trademark of Novo Nordisk A/S. Transformation Health is not affiliated with or endorsed by Novo Nordisk. Transformation Health does not accept payment from providers. How we make money.